Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04748432
Other study ID # omurilban
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 25, 2019
Est. completion date December 31, 2020

Study information

Verified date March 2024
Source Konya Numune Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Nonfermenting Gram-Negative Bacilli (NFGNB) are aerobic, non-motile, non-lactose fermenting, oxidase-negative, catalase-positive coccobacilli that pose a serious threat to critically ill patients. Primarily Pseudomonas aeruginosa (PA) and Acinetobacter baumannii (AB), are NFGNB which are potential multi-drug resistant (MDR) pathogens that are related to ventilator-associated pneumonia (VAP). In Nonfermenting Gram-Negative Bacilli (NFGNB) infections, which are potential multi-drug resistant (MDR) pathogens, pathogenesis is determined not only by bacterial virulence factors but more importantly by the interaction between bacteria and the host immune system. Thanks to their direct immunomodulatory properties, lipoproteins and lipids bind and neutralise toxic bacterial substances. During the acute phase response and inflammation, HDL presents significant structural and functional changes. This study was planned to evaluate the relationship between the changes of the serum lipid metabolism and other inflammation markers with the antimicrobial resistance status and the results in NFGNB VAP patients. Also, we aimed to investigate whether there is a difference in the clinical characteristics of the patients depending on the resistance profile of NFGNB.


Description:

This prospective study was performed in adult intensive care unit (ICU) patients. They were intubated endotracheally and received mechanical ventilation (MV) treatment for at least 48 hours in Konya Numune Hospital ICU, which has 42 surgery and medicine beds. The study was conducted between May 2019 and December 2020 and approved by the Ethics Committee of Necmettin Erbakan University Medical School. Informed consents were obtained from the patients who participated in the study or from their relatives. The characteristics of the patients and the sequential changes of the inflammatory response including the lipid profile were recorded.


Recruitment information / eligibility

Status Completed
Enrollment 131
Est. completion date December 31, 2020
Est. primary completion date December 15, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - ICU Patients of 18 years of age and above, with clinical suspicion of VAP as defined in the American Thoracic Society (ATS) guidelines and a simplified version of Clinical Pulmonary Infection Score (CPIS)> 6, with significant NFGNB growth in respiratory cultures and with no signs and symptoms of infection at the time of admission, were included in the study. Exclusion Criteria: - Patients with chronic inflammatory disease, hepatic dysfunction, active tuberculosis, malignancy, malnutrition, severe immunosuppression (i.e., neutropenia, HIV positive, organ transplant, having received immunosuppressants or used = 20 mg/day prednisone for two or more weeks in the preceding three months), those that within 72 hours since being included in the study had any extrapulmonary infection other than VAP, as well as those whose respiratory cultures presented bacterial agents other than NFGNB and fungal agents were not included in the study.

Study Design


Locations

Country Name City State
Turkey Konya Numune Hospital Konya

Sponsors (1)

Lead Sponsor Collaborator
Konya Numune Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Serum lipid metabolism The relationship between the changes of the serum lipid metabolism including total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and triglycerides with the antimicrobial resistance status and the results in NFGNB VAP patients 18 months
Secondary Clinical outcome The secondary outcome were the 30-day mortality rate of the patients depending on the resistance profile of NFGNB 18 months
See also
  Status Clinical Trial Phase
Completed NCT03577223 - Egg Effects on the Immunomodulatory Properties of HDL N/A
Completed NCT01143493 - The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease
Completed NCT03689738 - Effects of Potato Resistant Starch Intake on Insulin Sensitivity, Related Metabolic Markers and Satiety N/A
Completed NCT00905892 - Metabolic Fate Modifications of Saturated Fats After an Overfeeding N/A
Completed NCT03270527 - RISSCI-1 Blood Cholesterol Response Study N/A
Completed NCT01779245 - Effect of High-calcium Intake on Substrate Metabolism During Exercise N/A
Completed NCT03324191 - Tea Extract, Blood Lipid and Dietary Fat N/A
Completed NCT03757767 - The Fasting Study - Unraveling the Mechanistic Effects of Prolonged Fasting in Humans. N/A
Completed NCT05282641 - Effects of 10-gram Collagen Protein Hydrolysate on Cardiometabolic Health N/A
Completed NCT03648112 - Effects of Beta-glucan From Barley and Oats on Glucose and Lipid Metabolism, and Satiety N/A
Recruiting NCT04851041 - Effects of a Potato-based Food Pattern vs a Rice / Pasta-based Food Pattern on Cardiometabolic Health N/A
Completed NCT05313594 - Digital Twin - Modelling Postprandial Triglyceride and Glucose Responses
Terminated NCT05297032 - Effects of Quercetin on Metabolic Health N/A
Completed NCT05297825 - Twins Nutrition Study (TwiNS): Vegan vs. Omnivore N/A
Recruiting NCT03287518 - Evaluation of the Benefit and Tolerability of WAK2017 on Endothelial Function, Blood Pressure and Lipid Profile N/A
Completed NCT00227500 - Pravastatin for Hyperlipidaemia in HIV. Phase 4
Recruiting NCT04894526 - Alternating Energy Intake and Blood Fat Content After a Meal N/A
Completed NCT03029364 - Body Composition and Lipid Metabolism at Rest and During Exercise: A Cross-Sectional Analysis.
Completed NCT01921075 - Physiologic Plasticity of Intramyocardial Lipid Storage N/A
Completed NCT00620360 - Acute Effect of Fructose on Lipid Metabolism and Gender Differences N/A